Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder

Anxiety Disorders Clinical Trial

— REMOTE  

Official title:

REMOTE: Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder: Smartphone and Wearable Sensors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03991650
• Other study ID #: humanITcare: Remote
• Status: Completed
• Start date: February 1, 2019
• Est. completion date: November 5, 2019

Study information

• Verified date: January 2023
• Source: humanITcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The objective of this study is to analyze the physiological patterns of two groups of patients, one control and one with anxiety disorder and alcoholic abuse disorder using sensor data from mobile devices and wearables. This data will be compared to the data presented by three clinical questionnaires: State-trait Anxiety Inventory (STAI), the Alcohol Use Disorders Identification Test (AUDIT), and the Beck's Depression Inventory (BDI-II) in order to determine the feasibility of remote collected data.

Description:

The objective of this study is to analyze the physiological patterns of two groups of patients, one control and one with anxiety disorder and alcoholic abuse disorder using sensor data from mobile devices and wearables. This data, collected by sensors, will be compared to the data presented by three clinical questionnaires: State-trait Anxiety Inventory (STAI), the Alcohol Use Disorders Identification Test (AUDIT), and the Beck's Depression Inventory (BDI-II) in order to determine the feasibility of using remote collected data in routine clinical practice. Furthermore, patient satisfaction with the app will be evaluated after the data collection phase. This is a unicentric, case-controlled, longitudinal, evaluational, national study with two groups, one control of healthy individuals without symptoms of anxiety or depression, and another experimental group in which participants fulfill the given selection criteria for the trial. There are a total of 60 participants split evenly between the two groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: November 5, 2019
• Est. primary completion date: November 5, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 18-65 years of age.
• Alcohol use disorder (DSM 5) as main substance.
• Anxiety (STAI > percentile 33) and, if depressive symptoms, not clinically relevant as to accomplish DSM5 diagnostic criteria for mood disorders (major depressive disorder, bipolar disorder…).
• Having a mobile phone compatible with Android.
• Sign informed consent.

Exclusion Criteria:

• Mood disorder diagnoses (DSM5).
• Cognitive deficits that prevent the participation.
• Active intake of other substances (except for nicotine).

Related Conditions & MeSH terms

• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism
• Anxiety Disorders
• Depressive Disorder
• Disease

Intervention

Behavioral:
• Monitoring with a device
Participants will be monitored by an App.

Locations

Country	Name	City	State
Spain	Hospitcal Clínic de Barcelona	Barcelona

Sponsors (3)

Lead Sponsor	Collaborator
humanITcare	European Institute of Innovation and Technology, Hospital Clinic of Barcelona

Country where clinical trial is conducted

Spain, 

References & Publications (17)

Alonso J, Liu Z, Evans-Lacko S, Sadikova E, Sampson N, Chatterji S, Abdulmalik J, Aguilar-Gaxiola S, Al-Hamzawi A, Andrade LH, Bruffaerts R, Cardoso G, Cia A, Florescu S, de Girolamo G, Gureje O, Haro JM, He Y, de Jonge P, Karam EG, Kawakami N, Kovess-Masfety V, Lee S, Levinson D, Medina-Mora ME, Navarro-Mateu F, Pennell BE, Piazza M, Posada-Villa J, Ten Have M, Zarkov Z, Kessler RC, Thornicroft G; WHO World Mental Health Survey Collaborators. Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depress Anxiety. 2018 Mar;35(3):195-208. doi: 10.1002/da.22711. Epub 2018 Jan 22. — View Citation

Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015 Sep;17(3):327-35. doi: 10.31887/DCNS.2015.17.3/bbandelow. — View Citation

Barrio P, Ortega L, Lopez H, Gual A. Self-management and Shared Decision-Making in Alcohol Dependence via a Mobile App: a Pilot Study. Int J Behav Med. 2017 Oct;24(5):722-727. doi: 10.1007/s12529-017-9643-6. — View Citation

Bernert RA, Hom MA, Iwata NG, Joiner TE. Objectively Assessed Sleep Variability as an Acute Warning Sign of Suicidal Ideation in a Longitudinal Evaluation of Young Adults at High Suicide Risk. J Clin Psychiatry. 2017 Jun;78(6):e678-e687. doi: 10.4088/JCP.16m11193. — View Citation

Ghandeharioun, A., Fedor, S., Sangermano, L., Ionescu, D., Alpert, J., Dale, C., ... & Picard, R. (2017, October). Objective assessment of depressive symptoms with machine learning and wearable sensors data. In Affective Computing and Intelligent Interaction (ACII), 2017 Seventh International Conference on (pp. 325-332). IEEE.

Gustafson DH, McTavish FM, Chih MY, Atwood AK, Johnson RA, Boyle MG, Levy MS, Driscoll H, Chisholm SM, Dillenburg L, Isham A, Shah D. A smartphone application to support recovery from alcoholism: a randomized clinical trial. JAMA Psychiatry. 2014 May;71(5):566-72. doi: 10.1001/jamapsychiatry.2013.4642. — View Citation

Hsin H, Torous J, Roberts L. An Adjuvant Role for Mobile Health in Psychiatry. JAMA Psychiatry. 2016 Feb;73(2):103-4. doi: 10.1001/jamapsychiatry.2015.2839. No abstract available. — View Citation

Insel TR. Digital Phenotyping: Technology for a New Science of Behavior. JAMA. 2017 Oct 3;318(13):1215-1216. doi: 10.1001/jama.2017.11295. No abstract available. — View Citation

Menger V, Spruit M, Hagoort K, Scheepers F. Transitioning to a Data Driven Mental Health Practice: Collaborative Expert Sessions for Knowledge and Hypothesis Finding. Comput Math Methods Med. 2016;2016:9089321. doi: 10.1155/2016/9089321. Epub 2016 Aug 17. — View Citation

Onnela JP, Rauch SL. Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health. Neuropsychopharmacology. 2016 Jun;41(7):1691-6. doi: 10.1038/npp.2016.7. Epub 2016 Jan 28. No abstract available. — View Citation

Reddy MS. Depression: the disorder and the burden. Indian J Psychol Med. 2010 Jan;32(1):1-2. doi: 10.4103/0253-7176.70510. No abstract available. — View Citation

Saeb S, Lattie EG, Kording KP, Mohr DC. Mobile Phone Detection of Semantic Location and Its Relationship to Depression and Anxiety. JMIR Mhealth Uhealth. 2017 Aug 10;5(8):e112. doi: 10.2196/mhealth.7297. — View Citation

Saeb S, Zhang M, Karr CJ, Schueller SM, Corden ME, Kording KP, Mohr DC. Mobile Phone Sensor Correlates of Depressive Symptom Severity in Daily-Life Behavior: An Exploratory Study. J Med Internet Res. 2015 Jul 15;17(7):e175. doi: 10.2196/jmir.4273. — View Citation

Sano A, Taylor S, McHill AW, Phillips AJ, Barger LK, Klerman E, Picard R. Identifying Objective Physiological Markers and Modifiable Behaviors for Self-Reported Stress and Mental Health Status Using Wearable Sensors and Mobile Phones: Observational Study. J Med Internet Res. 2018 Jun 8;20(6):e210. doi: 10.2196/jmir.9410. — View Citation

Torous J, Staples P, Shanahan M, Lin C, Peck P, Keshavan M, Onnela JP. Utilizing a Personal Smartphone Custom App to Assess the Patient Health Questionnaire-9 (PHQ-9) Depressive Symptoms in Patients With Major Depressive Disorder. JMIR Ment Health. 2015 Mar 24;2(1):e8. doi: 10.2196/mental.3889. eCollection 2015 Jan-Mar. — View Citation

Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016 Sep;17(9):1245-9. doi: 10.15252/embr.201642951. Epub 2016 Aug 4. — View Citation

Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018. — View Citation

* Note: There are 17 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Self-reported Anxiety symptoms assessed with the State-Trait Anxiety Inventory (STAI)	Taken through the application "Ushine". Participants receive STAI scores ranging from 0-60, 0 being lowest amount of symptoms, and 60 being the greatest amount of symptoms, which are then transformed into percentiles according to age and sex.	One month, questionnaire taken 4 times (1/week)
Primary	Sleep pattern	Monitoring of circadian rhythm using a motion sensor Fitbit and cardiac activity sensor	One month
Primary	REM sleep time	monitoring of REM sleep patterns using a motion sensor Fitbit and cardiac activity sensor	One month
Primary	Heart Rate	monitoring of heart rate using Fitbit sensor	One month
Primary	Step count	Monitoring of daily step count using motion sensor FitBit	One month
Primary	Distance travelled	Monitoring of distance travelled using GPS phone	One month
Primary	Mobile device usage	Monitoring how often the patient's mobile device is used, determined by tracking the presence of a signal from their device	One month
Primary	Sociability (number of incoming an outgoing calls and text messages)	The number of incoming and outgoing calls and text messages will be monitored using the UShine app algorithm	One month
Primary	Change in Self-reported Depression symptoms assessed with the Beck's Depression Inventory (BDI-II)	Taken through the application "Ushine". Participants receive BDI-II scores ranging from 1-63, with a score of 0-13 indicating minimal depression, 14-19 indicating mild depression, 20-28 indicating moderate depression, and 29-63 indicating severe depression.	One month, questionnaire taken 4 times (1/week)
Primary	Change in Self-reported Alcohol Abuse Symptoms assesed with the Alcohol Use Disorders Identification Test (AUDIT)	Taken through the application "Ushine". Participants receive AUDIT scores ranging from 0-40. A score of 8 or more is associated with harmful or hazardous drinking, a score of 13 or more in women, and 15 or more in men, is likely to indicate alcohol dependence.	One month, questionnaire taken 4 times (1/week)
Secondary	Usability of the mobile application	Ease of usability of the mobile applications by participants will be scaled using the System Usability Scale (SUS). Final scores range from 0-100. A score of 51 or under means the system has serious faults in usability, a score of 68 means the system usability is about average, and a score of 80.3 or higher means the system usability is considered appreciable.	One month
Secondary	Satisfaction with the application	Participants' satisfaction with the Ushine application will be scaled using the Post-Study Usability Questionnaire (PSSUQ). Scores range from 0-100, 0 being least satisfactory and 100 being the most satisfactory. The PSSUQ has 3 sub-scores representing system usefulness, information quality, and interface quality, also scaled from 0-100. In all score sets, 0 is considered the least satisfactory and 100 is considered the most satisfactory.	One month

External Links

•   World Health Organization. Global Status Report on Alcohol and Health (2018).
•   World Health Organization. Mental depression and other common disorders: Global health estimates (2017).